|
|
|
|
|
|
|
Backward Thinking
|
|
Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
ADM Supports Clinical Trial into Effects of Probiotic Supplements for COVID-19 Patients in Hospital Care
ADM and Hospital de Sagunto, one of the largest medical
centers in the Valencia region, today announce their partnership for a
clinical trial into the effects of using a food supplement containing
live microbial strains to promote gut microbiome balance and help
improve health functions related to outcomes for COVID-19 patients in
high-risk groups.
On 18th March Dr Xavier Cortés, gastroenterologist at Hospital de
Sagunto, communicated with medical staff in China who had observed that
many COVID-19 patients had exhibited abnormal changes in their gut
microbiome.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Clinical Operations in Oncology Trials West Coast
17-18 November 2020, Hilton San Francisco Airport Bayfront
Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >> |
|
|
|
.jpg)
